1-3 of 3
Luciano Masini, M.D.
Close
Sort by
Journal Articles

A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.

Michele Cavo, M.D., Paola Tacchetti, M.D., Francesca Patriarca, M.D., Maria Teresa Petrucci, M.D., Lucia Pantani, M.D., Monica Galli, M.D., Francesco Di Raimondo, M.D., Claudia Crippa, M.D., Sara Bringhen, M.D., Massimo Offidani, M.D., Franco Narni, M.D., Vittorio Montefusco, M.D., Elena Zamagni, M.D., Tonino Spadano, M.D., Norbert Pescosta, M.D., Luca Baldini, M.D., Claudia Cellini, M.D., Tommaso Caravita, M.D., Antonio Ledda, M.D., Antonietta Falcone, M.D., Patrizia Tosi, M.D., Chiara Nozzoli, M.D., Renato Zambello, M.D., Luciano Masini, M.D., Paola Agostini, M.D., Mauro Fiacchini, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2009) 114 (22): 351.
https://doi.org/10.1182/blood.V114.22.351.351
Published: 2009
Journal Articles

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Elena Zamagni, M.D., Nicoletta Testoni, B.S., Carolina Terragna, B.S., Paola Tacchetti, M.D., Chiara Nicci, B.S., Patrizia Tosi, M.D., Mauro Fiacchini, M.D., Francesca Patriarca, M.D., Francesco Di Raimondo, M.D., Lucio Catalano, M.D., Francesco Casulli, M.D., Silvestro Volpe, M.D., Luciano Masini, M.D., Antonio Ledda, M.D., Annamaria Brioli, M.D., Delia Cangini, M.D., Alessandro Gozzetti, M.D., Catello Califano, M.D., Claudia Cellini, M.D., Affra Carubelli, M.D., Alessandro Petrucci, M.D., Giuliana Leopardi, M.D., Lucia Pantani, M.D., Michela Ceccolini, M.D., Massimo Offidani, M.D., Giulia Perrone, M.D., Michele Baccarani, M.D., Michele Cavo, M.D.
Journal: Blood
Blood (2009) 114 (22): 349.
https://doi.org/10.1182/blood.V114.22.349.349
Published: 2009
Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Michele Cavo, M.D., Nicoletta Testoni, B.S., Carolina Terragna, B.S., Giulia Marzocchi, B.S., Sandra Durante, B.S., Renato Zambello, M.D., Chiara Nozzoli, M.D., Lucia Pantani, M.D., Paola Tacchetti, M.D., Luciano Masini, M.D., Michela Ceccolini, M.D., Paola Agostini, M.D., Elena Zamagni, M.D., Valerio De Stefano, M.D., Patrizia Tosi, M.D., Daniele Derudas, M.D., Laura Dessanti, M.D., Stelvio Ballanti, M.D., Salvatore Palmieri, M.D., Andrea Nozza, M.D., Gioacchino Catania, M.D., Jacopo Peccatori, M.D., Alfonso D’Arco, M.D., Pellegrino Musto, M.D., Mariella Grasso, M.D., Maria Caterina Pallotti, M.D., Silvana Pasini, M.D., Pier Paolo Fattori, M.D., Anna Baraldi, M.D., Delia Cangini, M.D., Filippo Ballerini, M.D., Alessandro Petrucci, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2008) 112 (11): 1662.
https://doi.org/10.1182/blood.V112.11.1662.1662
Published: 2008